Connect with us

Life Sciences

Next-Generation mRNA Design: Increasing mRNA potency with a New Cap Analog

In this GEN webinar, Dr. Chunping Xu, Director of Chemistry R&D for TriLink Biotechnologies, will discuss the latest progress in next-generation mRNA…

Published

on

This article was originally published by GEN Genetic Engineering and Biotechnology News

Broadcast Date: June 15, 2023
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

mRNA vaccines and therapeutics are expanding rapidly, fueled in part by the extraordinary distribution and success of the COVID-19 vaccines. An essential part of the success of any mRNA therapeutic is the 5’ cap structure, which is critical to the stability and expression of an mRNA.

In this webinar, Dr. Chunping Xu, Director of Chemistry R&D for TriLink Biotechnologies, will discuss the latest progress in next-generation mRNA design. Attendees will learn about how major capping strategies differ in their manufacturing costs, time, complexity, and availability. In addition, Dr. Xu will show how TriLink is continuing to innovate in this technology as the company debuts a novel Cap1 structure.

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.

Chunping Xu
Chunping Xu
Director of Chemistry R&D
TriLink BioTechnologies

TriLink Biotechnologies logo

The post Next-Generation mRNA Design: Increasing mRNA potency with a New Cap Analog appeared first on GEN – Genetic Engineering and Biotechnology News.



Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Digital Health

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending